Biodesix (NASDAQ:BDSX) Earns “Outperform” Rating from William Blair

William Blair reissued their outperform rating on shares of Biodesix (NASDAQ:BDSX) in a research report sent to investors on Tuesday,RTT News reports. William Blair also issued estimates for Biodesix’s Q1 2025 earnings at ($0.08) EPS, Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.22) EPS, Q1 2026 earnings at ($0.05) EPS, Q2 2026 earnings at ($0.03) EPS, Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at ($0.03) EPS and FY2026 earnings at ($0.14) EPS.

Biodesix Trading Down 2.3 %

NASDAQ:BDSX opened at $0.85 on Tuesday. The stock has a market cap of $123.65 million, a price-to-earnings ratio of -2.18 and a beta of 1.10. The company has a debt-to-equity ratio of 1.30, a quick ratio of 3.40 and a current ratio of 3.40. Biodesix has a 1 year low of $0.64 and a 1 year high of $2.04. The business has a fifty day moving average of $1.08 and a 200-day moving average of $1.40.

Biodesix (NASDAQ:BDSX) last announced its earnings results on Monday, March 3rd. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01. Biodesix had a negative net margin of 66.84% and a negative return on equity of 275.79%. The firm had revenue of $20.43 million during the quarter, compared to analyst estimates of $19.92 million. Equities analysts predict that Biodesix will post -0.35 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Scott Hutton sold 83,660 shares of Biodesix stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $0.92, for a total transaction of $76,967.20. Following the transaction, the chief executive officer now directly owns 701,947 shares of the company’s stock, valued at $645,791.24. The trade was a 10.65 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 128,702 shares of company stock valued at $118,406 over the last quarter. Corporate insiders own 69.20% of the company’s stock.

Hedge Funds Weigh In On Biodesix

Large investors have recently made changes to their positions in the business. AIGH Capital Management LLC grew its position in Biodesix by 8.8% during the 4th quarter. AIGH Capital Management LLC now owns 6,179,812 shares of the company’s stock worth $9,455,000 after purchasing an additional 500,000 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new position in Biodesix in the 3rd quarter worth $10,849,000. Birchview Capital LP lifted its position in shares of Biodesix by 0.7% during the 4th quarter. Birchview Capital LP now owns 5,581,176 shares of the company’s stock worth $8,539,000 after purchasing an additional 40,000 shares during the last quarter. Silverarc Capital Management LLC grew its stake in shares of Biodesix by 21.7% in the fourth quarter. Silverarc Capital Management LLC now owns 4,332,281 shares of the company’s stock worth $6,628,000 after acquiring an additional 771,187 shares during the last quarter. Finally, Samjo Management LLC bought a new position in shares of Biodesix during the 4th quarter worth about $3,790,000. Institutional investors own 20.96% of the company’s stock.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.